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Abstract 
Major depressive disorder (MDD) in the elderly is a risk factor for dementia, but the 
precise biological basis remains unknown, hampering the search for novel 
biomarkers and treatments. In this study, we performed metabolomics analysis of 
cerebrospinal fluid (CSF) from cognitively intact elderly patients (N = 28) with 
MDD and age- and gender-matched healthy controls (N = 18). The CSF levels of 177 
substances were measured, while 288 substances were below the detection limit. 
Only ascorbic acid was significantly different, with higher levels in the MDD group 
at baseline. There were no correlations between CSF ascorbic acid levels and clinical 
variables in MDD patients at baseline. At the 3-year follow-up, there was no 
difference of CSF ascorbic acid levels between two groups. There was a negative 
correlation between CSF ascorbic acid and CSF amyloid-ȕ42 levels in all subjects. 
However, there were no correlations between ascorbic acid and other biomarkers 
(e.g., amyloid-ȕ40, total and phosphorylated tau protein). This preliminary study 
suggests that abnormalities in the transport and/or release of ascorbic acid might play 
a role in the pathogenesis of late-life depression.  
Key words: Ascorbic acid; Biomarker; CSF; Late-life depression; Oxidative stress 
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Introduction 
Late-life depression, one of the most common psychiatric disorders in older adults, is 
a growing public health concern as the global population ages. Late-life depression is 
associated with significant functional impairment, high recurrence rates, chronicity, 
variable treatment response, and high rates of medical comorbidity and mortality 
(1-6). Multiple lines of evidence suggest that late-life depression is a risk factor for 
the development of mild cognitive impairment and dementia, including Alzheimer’s 
disease (AD) and vascular dementia (3,7-10). However, the precise molecular 
mechanisms underlying the relationship between late-life depression and dementia 
risk remain unknown. A precise understanding of this relationship would likely 
contribute to improving preventive interventions in the elderly. .  
Metabolomics is the profiling of small molecule metabolites and provides the 
potential to characterize specific metabolic phenotypes associated with a disease. 
Metabolomics has an advantage over other “omics” techniques in that it directly 
samples the metabolic changes in an organism and integrates information from 
changes at the gene, transcript, and protein levels, as well as posttranslational 
modifications (10-14). Cerebrospinal fluid (CSF) is arguably the most relevant 
sampling substrate for the in vivo study of brain disorders as it reflects the metabolic 
status and the biochemistry of the brain. Metabolomics analyses of CSF in patients 
and controls therefore have the potential to reveal protein differences linked to the 
pathogenesis of neuropsychiatric disorders that may have value as biomarkers and 
might be targets for novel treatments (15-22). We reported that the CSF ratio of 
glutamine/glutamate levels in elderly patients with MDD was significantly higher 
than that of age-matched healthy controls, and that the increased ratio in patients was 
significantly decreased after 3-year follow-up by medication in association with 
decreased depression symptoms over this time period, suggesting that abnormalities 
in the glutamine-glutamate cycle in the brain play a role in the pathogenesis of 
late-life depression (23). Furthermore, Pomara et al. (24,25) reported state-dependent 
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alterations in CSF amyloid-ȕ42 levels in cognitively intact elderly MDD patients. In 
agreement, a recent meta-analysis showed significant reduction of CSF amyloid-ȕ42 
levels in late-life depression (26), suggesting that elderly MDD patients have 
significant differences in amyloid-ȕ metabolism, with a change in CSF amyloid-ȕ42 
levels in the same direction observed in AD patients. However, there is, currently, no 
report that has evaluated the metabolomics analysis of CSF of elderly MDD patients.  
In the present study, we performed metabolomics analysis of CSF samples 
from elderly cognitive intact patients with MDD and age- and gender-matched 
healthy controls. Furthermore, we examined protein expression in postmortem brain 
samples from controls and psychiatric disorders including MDD patients. 
Results 
As reported previously (23-25), the two groups did not differ on any relevant clinical 
or demographic variable with the exception of the mean HAM-D score, which as 
expected was significantly higher in the MDD group (Table 1). Of note, the 
proportion of participants with a reported family history of AD was slightly higher in 
the control group than in the MDD group. The CSF levels of amyloid-ȕ42 in the 
MDD group were significantly lower than those of the control group, whereas 
differences in CSF levels of amyloid-ȕ40, total and phosphorylated tau protein did not 
differ across conditions (Table 1).  
We measured 475 major metabolic compounds from various pathways (e.g., 
glycolytic system, pentose phosphate pathway, citric acid cycle, urea cycle, 
polyamine-creatine metabolism pathway, purine metabolism pathway, glutathione 
metabolism pathway, nicotinamide metabolism pathway, choline metabolism 
pathway and diverse amino acid metabolism pathways). In this study, we were able 
to measure 177 metabolites, while 288 were below the detection limit. Interestingly, 
there was a significant (P = 0.0029) difference in CSF levels of ascorbic acid 
between the MDD (0.304 ± 0.061 mM, N = 28) and the control groups (0.240 ± 
0.075 mM, N = 18) (Table S1)(Table 2)(Figure 1). In addition, the analysis using 
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covariates (BMI, sex, medication) was also statistically significant (P = 0.0037). 
There were no significant differences in CSF levels of other substances between the 
MDD and the control groups at baseline (Table S1). At baseline there were no 
correlations between CSF ascorbic acid levels and clinical variables in the MDD 
patients (N = 28). No correlations between CSF ascorbic acid levels and other 
clinical variables were observed. There was a significant negative correlation 
(Spearman’s r = - 0.31, P = 0.037) between CSF ascorbic acid and CSF amyloid-ȕ42 
in the all subjects (N = 46)(Figure 2). However, there were no significant 
correlations between ascorbic acid and other biomarkers (e.g., amyloid-ȕ40, total and 
phosphorylated tau protein) (data not shown). In addition, APOE e4 did not affect 
CSF levels of ascorbic acid in control and MDD groups (data not shown). 
At the 3-year follow-up, there was no difference of CSF ascorbic acid levels 
between two groups although the HAM-D scores in the elderly MDD patients were 
significantly decreased after medication (Table 2). Furthermore, there were no 
correlations between ascorbic acid and other biomarkers (e.g., amyloid-ȕ40, total and 
phosphorylated tau protein) (data not shown).  
Ascorbic acid (vitamin C) is controlled in the brain parenchyma via the 
sodium dependent vitamin C transporter, SVCT2, which transfers ascorbic acid at the 
choroid plexus from blood into CSF, and also from extracellular fluid into neurons 
(27). Using Western blot analysis, we measured the expression of SVCT2 in the 
postmortem samples from the parietal cortex and cerebellum from controls and 
psychiatric disorders, including MDD, bipolar disorder (BD), and schizophrenia. 
There was no statistical difference among the four groups (Table 3). 
Discussion 
In the present study, we found that elderly patients with MDD showed increased CSF 
levels of ascorbic acid compared to age-matched healthy controls, although CSF 
levels of other metabolites were not different. Furthermore, we found a negative 
correlation between CSF ascorbic acid and CSF amyloid-ȕ42 in the all subjects. 
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Given the possible role of CSF amyloid-ȕ42 in the pathogenesis of late-life 
depression (24,25,28-30), these findings suggest that abnormalities in the brain levels 
of ascorbic acid might play a role in the depressive symptoms of elderly MDD 
patients. To our knowledge, this is the first report in the literature of an increase in CSF 
ascorbic acid in elderly MDD patients, suggesting abnormalities in the transport 
and/or release of the antioxidant ascorbic acid in the brains of elderly depressed 
individuals.  
Ascorbic acid is a potent water-soluble antioxidant which is not synthesized in 
the brain. Approximately 40% of ascorbic acid in the brain turns over each day. 
Ascorbic acid levels are maintained as high as 10 µM in neurons (27,31), suggesting 
that ascorbic acid is crucial for maintenance of oxidative balance. Under conditions 
of ascorbic acid deficiency, brain content of ascorbic acid is retained tenaciously, 
with decreases of less than 2% per day (27,31). Decreased brain levels of ascorbic 
acid by deficient diet of ascorbic acid may cause dangerous levels of oxidative stress 
during normal aging, and particularly during inflammatory neurodegenerative 
diseases including AD. Thus, brain levels of ascorbic acid are under strong 
homeostatic regulation (27,31). Given the role of oxidative stress and inflammation 
in late-life depression (32-36), it is likely that abnormalities in CSF ascorbic acid 
associated with oxidative stress may play a role in the pathophysiology of late-life 
depression.  
     It has been reported that CSF levels of ascorbic acid in humans were higher 
than blood (37-39), supporting ascorbic acid as a “nourishing liquor” that constantly 
surrounds the brain (40). At the choroid plexus, ascorbic acid is actively transported 
across the basolateral membrane by SVCT2 into the epithelium and then released 
into the CSF (31,39). In this study, we found higher CSF levels of ascorbic acid in 
elderly patients with MDD, suggesting that higher CSF levels of ascorbic acid 
depends on both active “carrier” transport processes and “barrier” integrity of the 
blood-brain barrier. This may be necessary to prevent ascorbic acid from diffusing 
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out of the brain driven by the concentration gradient (39). However, we did not find 
any changes in the expression of SVCT2 in the postmortem brain samples from 
MDD. Nonetheless, further research on the role of SVCT2 in the transport of 
ascorbic acid is needed. 
It has also been reported that the CSF: plasma ratio of ascorbic acid in AD 
patients was higher than that in controls (39,41-43), suggesting increased 
consumption of ascorbic acid as a result of oxidative stress in the AD brain, leading 
to lower plasma levels (39). In 32 adults followed for one year with 
mild-to-moderate AD, the rates of cognitive decline were not explained by CSF or 
plasma ascorbic acid independently (39). Taken together, it seems that increased CSF 
levels of ascorbic acid in elderly MDD patients may be due to an increased transport 
of ascorbic acid into CSF from blood although plasma levels of ascorbic acid were 
not measured in this study. Further precise studies underlying the reasons of higher 
CSF levels of ascorbic acid are needed. 
A recent study using [11C]PK11195 and positron emission tomography 
demonstrated an increased microglial activation in the brain from patients with 
late-life depression (44), suggesting neuroinflammation (or oxidative stress) in the 
brain in elderly MDD patients. It is well known that peripheral inflammatory 
substances (e.g., C-reactive protein, interleukin (IL)-8, IL-6, tumor necrosis factor 
(TNF)-α) are higher in patients with late-life depression (35,36). Furthermore, 
immunological biomarkers, such as vascular endothelial growth factor (VEGF), the 
chemokine eotaxin, TNF-α, interferon-Ȗ, and macropharge inflammatory protein-1α, 
are associated with brain structure in late-life depression (36). Taken together, it is 
likely that compensatory responses to oxidative stress in the brain of elderly MDD 
patients may contribute to the increased CSF levels of ascorbic acid although further 
detailed study on this hypothesis is needed.  
We previously reported a reduction of amyloid-ȕ42 in the same MDD patients 
at baseline (24). Interestingly, we found a negative correlation between CSF ascorbic 
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acid and CSF amyloid-ȕ42 in the all subjects, suggesting a close relationship between 
these two biomarkers. Importantly, CSF ascorbic acid in elderly MDD patients was 
no longer significantly different from controls after a 3-year period; the loss of 
significance coincided with reduction in the severity of depressive symptoms, 
suggesting that abnormalities in CSF ascorbic acid in elderly depression 
may be state-dependent. Furthermore, Pomara et al. (24) reported higher CSF levels 
of isoprostane, a biomarker for oxidative stress, in the same patients with MDD. 
However, there was no correlation between CSF ascorbic acid and CSF isoprostane 
in all the subjects (data not shown). Taken together, these findings highlight that static 
indices such as levels of ascorbic acid either in CSF or brain reflect dynamic and brain 
region specific alterations in the oxidative balance.    
      Humans have lost the ability to synthesize ascorbic acid (27). A 
cross-sectional and prospective study showed that use of ascorbic acid supplement is 
associated with reduced prevalence and incidence of AD, suggesting the 
effectiveness of dietary supplementation of ascorbic acid in older adults (45). A 
recent meta-analysis showed that serum levels of ascorbic acid in patients with MDD 
were lower than controls, and that serum levels of ascorbic acid in patients with 
MDD were increased after antidepressant therapy (46). Therefore, it is possible that 
supplementation of ascorbic acid in elderly patients with MDD may contribute to 
reduced prevalence of AD. 
Finally, there are some limitations to this preliminary study that should be 
noted. The main limitation was small sample size, and similar, future studies in 
late-life depression would likely benefit from larger sample sizes. In this study, we 
did not use the multiple test correction since the purpose of this study was the global 
analysis of a number of metabolites as a pilot study. Follow-up study with much 
more samples should be conducted to validate our pilot findings. Another limitation 
was that we did not measure plasma ascorbic acid in the subjects of this study. Given 
the role of CSF: plasma ratio of ascorbic acid (39,42,43), it is of great interest to 
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study the relationship between CSF: plasma ratio of ascorbic acid and late-life 
depression. 
     In conclusion, we found that the CSF levels of ascorbic acid in elderly patients 
with MDD were significantly higher than that of age-matched healthy controls. 
These preliminary findings suggest that oxidative imbalance in the brain reflected by 
abnormalities in CSF ascorbic acid play a role in the pathogenesis of late-life 
depression. Further studies measuring CSF and plasma levels of ascorbic acid using 
larger cohorts, particularly cohorts of antidepressant-naïve MDD patients, will be of 
great interest. 
Materials and Methods 
Participants 
This study was approved by the institutional review boards of the Nathan Kline 
Institute for Psychiatric Research and the New York University School of Medicine. 
Metabolomics analysis of this study was approved by Research Ethics Committee of 
the Graduate School of Medicine, Chiba University. All methods were performed in 
accordance with the guidelines and regulation of the National Institutes of Health, 
USA. Participants were volunteers who responded to advertisements in local 
newspapers and flyers or were recruited from the Memory Education and Research 
Initiative Program (24). All participants provided informed consent prior to 
examination and received up to $450.00 in compensation. A total of 133 participants 
completed the baseline evaluation, and 51 of these took part in the optional lumbar 
puncture procedure. Of these 51 participants, three were excluded because of 
evidence in their MRI scans of confluent deep or periventricular white matter 
hyperintensities, defined as one or more hyperintense lesions measuring at least 10 
mm in any direction. One individual was excluded because of a Mini-Mental State 
Examination (MMSE) score below 28. Of the 47 remaining participants, 28 were 
diagnosed with MDD by a board-certified psychiatrist, leaving 18 comparison 
subjects. The structural interview for DSM-IV disorders (SCID) was administered by 
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a psychiatrist to establish an MDD diagnosis. Of the 28 patients with MDD, 21 
(75%) had recurrent episodes. Table 1 summarizes the demographic and clinical 
characteristics of the study participants at baseline. 
Procedure 
The study was conducted over four visits, usually one week apart. The first three 
visits were conducted at the Nathan Kline Institute for Psychiatric Research and the 
Clinical and Translational Science Institute, New York University Langone Medical 
Center. During the first visit, for the purpose of obtaining informed consent, study 
procedures were explained and participants were informed of their rights. 
Participants’ medical and psychiatric histories, including family history of AD, were 
also obtained, and their vital signs were measured. Participants then underwent a 
psychiatric evaluation, and their global cognitive status was assessed using the 
MMSE. Additionally, the Hamilton Depression Rating Scale (HAM-D) was 
administered to rate the severity of current depressive symptoms. Subjects who met 
the criteria for past MDD but were not currently depressed (i.e., HAM-D score below 
16) were included as MDD subjects. Blood was drawn for routine clinical labs and 
APOE genotyping. During the second visit, participants underwent an MRI scan of 
the head to quantify the magnitude of vascular brain pathology. During the third visit, 
subjects underwent a comprehensive neuropsychological assessment, including the 
Buschke Selective Reminding Test (47), the Trail-Making Test, parts A and B (48), 
and the category fluency test (49).  
Finally, during the fourth visit, a lumbar puncture was performed by a 
neuroradiologist under guided fluoroscopy in a subset of participants. Prior to the 
procedure, which was performed between 9:00 a.m. and 10:00 a.m., participants 
were asked to fast overnight. A total of 15 ml of clear CSF was collected in three 
polypropylene tubes labeled “A” (first 5 ml), “B” (second 5 ml), and “C” (third 5 ml). 
The tubes were immediately placed on ice for a maximum of 1 hour until the samples 
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were centrifuged at 4°C (at 1500 rpm) for 10 minutes. Then, aliquots of 0.25 ml were 
placed into 1.00-ml polypropylene cryogenic vials and put into Nunc eight-cell 
storage boxes (Nalge Nunc International, Rochester, N.Y.) at -80°C. All amyloid-ȕ, 
tau, and amino acids determinations were performed from tube “C”. 
Among these participants, MDD patients (N=19) and comparison control 
subjects (N=17) were followed for 3 years. The MDD patients were receiving 
antidepressant, such as including SSRIs (paroxetine, escitalopram, fluoxetine), 
SNRIs (venlafaxine, duloxetine), and mirtazapine (23,24). Clinical data, including 
physical examination, routine laboratory tests, psychiatric evaluations, HAM-D 
rating scale, cognitive functions, and CSF samples were collected at 3-year 
follow-up. 
Metabolomics analysis of human CSF samples 
Metabolomics analyses of CSF samples from the MDD and control groups were 
performed at the Chemicals Evaluation and Research Institute, Japan (CERI, Tokyo, 
Japan) using an GC-MS/MS based multiple reaction monitoring metabolomics 
platform. GC/MS/MS analysis was performed using a GCMS-TQ8030 (Shimadzu 
Co., Kyoto, Japan) with a fused silica capillary column (BPX-5; 30 m × 0.25 mm 
inner diameter, film thickness: 0.25 µm; SGE Analytical science by Trajan Scientific 
Australia Pty Ltd). Quantifications of the metabolites were conducted with the 
built-in GCMS Solution software (Ver.4.20, Shimadzu) and GC/MS/MS Smart 
Metabolites Database (Ver. 2.0, Shimadzu). In this study, 475 major metabolic 
compounds from various pathways (glycolytic system, pentose phosphate pathway, 
citric acid cycle, urea cycle, polyamine-creatine metabolism pathway, purine 
metabolism pathway, glutathione metabolism pathway, nicotinamide metabolism 
pathway, choline metabolism pathway and diverse amino acid metabolism pathway) 
were selected for metabolomics analysis (Table S1).  
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Western blot analysis  
Postmortem brain samples (parietal cortex and cerebellum) from control, major 
depressive disorder (MDD), bipolar disorder (BD), and schizophrenia were obtained 
from the Neuropathology Consortium of the Stanley Medical Research Institute (MD, 
USA) (Table S2) (50-52). Tissue samples were homogenized in Laemmli lysis buffer, 
and total protein levels were measured using the DC protein assay kit (Bio-Rad, 
Hercules, CA, USA). Aliquots (50 μg of total protein) were incubated for 5 min at 
95 °C, with an equal volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol, 0.1% 
bromophenol blue, 10% ȕ-mercaptoethanol, 4% sodium dodecyl sulfate, and 
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, using 
Mini-PROTEAN® TGX Stain-Free™ Gels (AnykD, cat #: 456-8125, Bio-Rad). 
Proteins were transferred onto polyvinylidenedifluoride (PVDF) membranes using a 
Trans Blot Mini Cell (Bio-Rad). For immunodetection, the blots were blocked with 
3% BSA in TBST (TBS + 0.1% Tween-20) for 1 h at room temperature (RT), and 
kept with primary antibodies overnight at 4°C. Membranes were probed using a 
sodium-ascorbate co-transporter 2 (SVCT2) antibody (cat #: sc-9926, 1: 200, Santa 
Cruz Biotechnology, CA, USA). The next day, membranes were washed three times 
in TBST, and incubated with horseradish peroxidase conjugated anti-goat antibody 1 
hour, at RT. After final three washes with TBST, the bands were detected using 
enhanced chemiluminescence (ECL) prime the Western Blotting Detection system 
(GE Healthcare Bioscience, Tokyo, Japan). The blots then were incubated in the 
stripping buffer (2% SDS, 100 mM ȕ-mercaptoethanol, 62.5 mM Tris/HCL PH 6.8) 
for 30 min at 60°C followed by three time washed with TBST. The stripped blots 
were kept blocking solution for 1 hour and incubated with the primary antibody 
directed against ȕ-actin. Images were captured with a Fuji LAS3000-mini imaging 
system (Fujifilm, Tokyo, Japan), and immunoreactive bands were quantified. 
Statistical analysis 
First, Student t-test, and Fisher’s exact test were used to compare the MDD and 
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control groups on MMSE scores, years of education, body mass index, age, 
incidence of diabetes, gender, APOE genotypes, and reported family history of AD 
(Table 1). Second, Student t-test was used to compare the two diagnostic groups with 
respect to all remaining CSF variables. Data of 3-year follow-up were analyzed using 
two-way repeated multivariate analysis of variance (MANOVA). Spearman’s rank 
correlation coefficient was used. All tests were two-tailed, and statistical significance 
was established at an α of 0.05, unless differently noted. All analyses were conducted 
using SPSS 22 (SPSS, Inc., Chicago) and SAS Ver. 9.4 (SAS Institute, Cary, North 
Carolina, USA). 
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Figure legends 
Figure 1. CSF levels of ascorbic acid in control and MDD groups 
There was a significant (P = 0.0029) difference in CSF levels of ascorbic acid 
between the control groups (0.240 ± 0.075 mM, N = 18) and MDD (0.304 ± 0.061 
mM, N = 28). 
Figure 2. Correlations between CSF ascorbic acid and CSF amyloid-β42 
There was a significant negative correlation (r = - 0.31, P = 0.037) between CSF 
ascorbic acid and CSF amyloid-ȕ42 in the all subjects (N = 46). 
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Table 1. Demographic and Clinical Characteristics of Cognitively Intact Individuals with MDD and Age-Matched Control Subjects at Baseline 
Characteristic Control Group MDD Group Statistical Analysis 
  (N=18) (N=28) P Value 
Age (years) 67.3 ± 6.7 66.5 ± 5.4 0.67 
Education (years)a 16.6 ± 2.8 16.5 ± 2.7 0.86 
Body mass index 28.4 ± 4.6 28.8 ± 6.7 0.85 
21-item HAM-D 1.1 ± 1.9 14.9 ± 8.8 <0.001 
MMSE 29.5 ± 0.5 29.8 ± 0.6 0.17 
Total recall rating 65.1 ± 12.3 64.9 ± 13.9 0.95 
Delayed recall rating 8.5 ± 2.9 9.5 ± 2.5 0.24 
Trail-Making Test score 
    Part A 36.3 ± 12.0 36.0 ± 14.1 0.95 
    Part B 81.2 ± 32.2 86.1 ± 23.2 0.55 
Category fluency test 42.4 ± 7.7 40.6 ± 8.2 0.46 
  N (%) N (%) P Value 
Diabetes 4 (22) 5 (18) 0.72 
Female 11 (61) 10 (36) 0.13 
Family history of Alzheimer's disease 5 (28) 3 (11) 0.69 
  N (%) N (%) P Value 
Apolipoprotein genotype 
     APOE e4 positive 4 (22) 11 (39)  
     APOE e4 negative 14 (78) 17 (61) 0.35 
  pg/ml pg/ml P Value 
Amyloid-b42 340.2 ± 186.8 224.7 ± 125.1 0.02 
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Amyloid-b40 6374.7 ± 2689.0 5146.0 ± 2369.0 0.11 
Total tau proteinb 311.0 ± 134.3 273.0 ± 114.3 0.31 
Phosphorylated tau protein 49.7 ± 19.7 48.9 ± 25.9 0.92 
The data are the mean ± standard deviation (SD). 
21-item HAM-D: 21-item Hamilton Depression Rating Scale, MMSE: Mini-Mental State Examination 
a Data for one control subject were not available. 
b Data for one MDD patient were not available. 
The data at baseline are from Pomara et al. (26). 
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Table 2. HAM-D score and CSF levels of ascorbic acid in subjects at baseline and 3-year follow-up 
Characteristic          Baseline    3-Year Follow-up   Statistical Analyses (P Values) 
 
  Control (N=18) MDD (N=28)  Control (N=17) MDD (N=19)  ME time  ME MDD Interaction 
 
21-item HAM-D 1.315 ± 1.565 13.67 ± 8.815  2.235 ± 6.01 8.478 ± 7.79  0.005  <0.001  <0.001 
 
Ascorbic acid  0.240 ± 0.075 0.304 ± 0.061  0.241 ± 0.095 0.270 ± 0.098  0.175  0.835  0.359 
(mM) 
The data are the mean ± standard deviation (S.D.). 
MDD: Major depressive disorder, 21 HAM-D: 21-item Hamilton Depression Rating Scale 
Analysis = 2x2 Repeated multivariate analysis of variance (MANOVA)  
ME time = Main effect of time (baseline and follow up), ME MDD = Main effect of MDD-status (depressed and controls) 
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Table 3. Expression of SVC2 in the parietal cortex and cerebellum from psychiatric disorders 
Brain regions Controls  MDD  BD  Schizophrenia  One-way ANOVA 
 
Parietal cortex 1.000 ± 0.052 0.896 ± 0.134 0.907 ± 0.099 0.969 ± 0.078  F (3,56) = 0.270, P = 0.846 
 
Cerebellum 1.000 ± 0.074 1.117 ± 0.104 0.948 ± 0.084 0.948 ± 0.123  F (3,56) = 0.661, P = 0.580 
 
The data are the mean ± S.D. (N = 15). 
MDD: Major depressive disorder, BD: Bipolar disorder 
The values were shown as the ration of SVCT2 to ȕ-actin. 
 
 
